Saxenda Users Join NAION Litigation as Vision-Loss Claims Expand to Liraglutide

What Happened

Product-liability litigation over GLP-1-linked vision loss has widened beyond Eli Lilly's drugs. Legal recruitment campaigns are now seeking liraglutide users — the active ingredient in Novo Nordisk's Saxenda weight-management injection and Victoza diabetes therapy — who developed sudden vision loss consistent with NAION (non-arteritic anterior ischemic optic neuropathy), a rare condition in which blood flow to the optic nerve is interrupted.

The complaints mirror the earlier claim wave against tirzepatide-based Zepbound and Trulicity: plaintiffs allege manufacturers failed to adequately warn about a rare ocular risk, citing observational research that associated incretin therapies with elevated NAION incidence. Novo Nordisk maintains that no causal link has been established and that the benefit-risk profile of its medicines is supported by extensive clinical trial programs.

Who Is Affected

• Patients who developed sudden vision loss in one eye after using liraglutide, who are now being recruited as potential claimants.
• Novo Nordisk, which faces the same class of ocular-injury allegations already aimed at its largest competitor.
• Prescribers, who are expected to discuss rare ocular symptoms during consent conversations for every incretin therapy.
• The wider GLP-1 category, because vision-loss headlines shape patient perception of the entire drug class, regardless of molecule.

Timeline

• 2010-2014 — Liraglutide reaches the market as Victoza and later Saxenda, building more than a decade of post-marketing safety data.
• 2024-2025 — Observational studies first link incretin therapies to elevated NAION risk; European regulators add sudden vision loss as a rare listed side effect for GLP-1 medicines.
• 2025-2026 — US courts begin receiving vision-loss lawsuits over tirzepatide products; by September 2026, claim campaigns broaden to liraglutide users.

What This Means for Researchers

The expansion to liraglutide is scientifically notable because the molecule is pharmacologically distinct from tirzepatide: a single GLP-1 receptor agonist rather than a dual GIP/GLP-1 agonist. Parallel allegations across both drugs raise a class-wide question — whether any association with NAION reflects the GLP-1 receptor pathway itself, rapid metabolic change, or confounding from the obesity and cardiovascular risk factors NAION already shares.

Liraglutide's long market history gives researchers an unusually deep baseline of real-world data to test against, and legal discovery will push adverse-event reporting into the public record, where it can sharpen or weaken the hypothesized association. The safest reading for now: allegations are not evidence, and causation remains unproven in court.

How to Verify Your Peptides

• Understand analytical fundamentals with how peptide testing works.
• Our semaglutide testing and purity guide walks through the HPLC workflow used for incretin-class compounds.
• Send batches for independent verification via the third-party peptide testing lab directory.

Safe Alternatives

• Read the complete clinical record in our liraglutide and semaglutide profiles before drawing conclusions from litigation coverage alone.
• Treat research-stage candidates such as retatrutide as requiring full analytical documentation.
• Source compounds only from vendors that publish batch-specific certificates of analysis.

Sources

• Industry reports
• Regulatory announcements